RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Cutaneous signs of liver disease: value for prognosis of severe fibrosis and cirrhosis.

BACKGROUND/AIMS: Although physicians have looked for cutaneous signs of liver disease for more than a century, their prognostic value has never been evaluated systematically.

METHODS: Therefore, cutaneous changes were prospectively recorded in all patients referred for liver biopsy from June 2000 to May 2004. Fibrosis was staged from F0 to F4 according to Desmet and Scheuer. The analysis included 744 patients, 520 of whom had chronic hepatitis C while the remaining had other diseases.

RESULTS: By univariate analysis, the frequency of several skin changes was associated with the degree of fibrosis. In general, at fibrosis F0-1 skin changes were infrequent; they became more frequent at F2 and were frequent at F3-4. To analyse the predictive value of skin changes, patients with fibrosis F0-2 were compared with those with F3-4. Final logistic regression included spider naevi, palmar erythema, teleangiectasia, bleeding signs and dry skin as well as age and gender. When routine laboratory values were included in the analysis, prothrombin time, gamma-glutamyltransferase and albumin proved to be significant. Receiver operating characteristic (ROC) showed a good discrimination of fibrosis F0-2 from F3-4 by the modelled score on combining skin changes and laboratory tests: at the cost of 2% of non-diagnosed patients with F3-4, one might have saved 60% of biopsies. ROC was less useful in discriminating fibrosis F0-1 from F2-4. The discriminative power of skin changes was better than the laboratory values and the aspartate aminotransferase/platelet ratio.

CONCLUSIONS: The results prove that it is quite useful to look for skin changes in patients with liver disease.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app